Krystal Biotech, Inc.
KRYS
$306.29
-$10.01-3.17%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 31.95% | 17.52% | 16.65% | 36.65% | 94.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.95% | 17.52% | 16.65% | 36.65% | 94.88% |
| Cost of Revenue | 25.76% | 33.20% | -36.22% | 19.24% | 107.85% |
| Gross Profit | 32.32% | 16.62% | 21.23% | 38.28% | 94.15% |
| SG&A Expenses | 25.63% | 32.48% | 31.06% | 27.27% | 25.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.68% | 26.27% | 15.46% | 15.27% | 31.69% |
| Operating Income | 48.10% | 7.00% | 18.31% | 86.59% | 523.31% |
| Income Before Tax | 40.93% | 5.19% | 61.13% | 191.52% | 4,577.79% |
| Income Tax Expenses | -29.93% | -108.59% | -1,312.75% | 1,669.81% | -- |
| Earnings from Continuing Operations | 56.53% | 13.02% | 192.00% | 146.23% | 3,734.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.53% | 13.02% | 192.00% | 146.23% | 3,734.01% |
| EBIT | 48.10% | 7.00% | 18.31% | 86.59% | 523.31% |
| EBITDA | 47.87% | 7.67% | 18.02% | 77.13% | 475.00% |
| EPS Basic | 54.00% | 11.70% | 189.61% | 143.55% | 3,669.30% |
| Normalized Basic EPS | 38.66% | 3.96% | 12.54% | 62.10% | 218.71% |
| EPS Diluted | 52.50% | 11.64% | 192.31% | 143.40% | 3,900.00% |
| Normalized Diluted EPS | 38.00% | 3.90% | 13.74% | 63.24% | 218.28% |
| Average Basic Shares Outstanding | 1.64% | 1.18% | 0.83% | 1.09% | 1.84% |
| Average Diluted Shares Outstanding | 2.13% | 1.23% | -0.23% | 0.38% | 1.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |